



Achillion Pharmaceuticals
 Investor Relations Department
 300 George St.
 New Haven, CT 06511
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: ACHN

| | |
|---------------|--|
| Last Trade: | 4.10 |
| Trade Time: | 2:26 PM ET Oct 23, 2017 |
| Change: | -0.05 ↓ (-1.205%) |
| Day Range | 4.00 - 4.18 |
| 52-Week Range | 3.15 - 7.10 |
| Volume | 2,837,216 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile


Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

Stock Performance



Press Releases [View all]

- Oct 23, 2017*
[Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir \(JNJ-4178\) at the 2017 Liver Meeting](#)
- Sep 20, 2017*
[Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series](#)
- Sep 11, 2017*
[Achillion Announces Strengthening of Management Team](#)
- Sep 11, 2017*
[Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen](#)
- Aug 8, 2017*
[Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor](#)

Financial Disclosures [View all]

- [Second Quarter Financial Results](#)
- Feb 23, 2017*
[Annual Report \(10-K\)](#)
- Apr 17, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*
[Quarterly Report \(10-Q\)](#)